<DOC>
	<DOCNO>NCT01067989</DOCNO>
	<brief_summary>Low-dose metronomic ( LDM ) chemotherapy well anti-inflammatory agent bisphosphonates show anti-angiogenic property tumor vasculature . This study mean test therapeutic potential anti-angiogenic treatment strategy combine agent metastatic breast cancer patient .</brief_summary>
	<brief_title>Low-Dose/Metronomic ( LDM ) Chemotherapy Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<criteria>Histologic proof infiltrate duct carcinoma breast . Her2 negative tumor . ECOG performance status : 01 . Presence measurable disease : primary and/or metastatic . CBC show normal value toxicity limit grade I. SMA show liver renal function &lt; 1.5 normal value previous treatment anthracycline taxane mandatory either neoadjuvant/adjuvant treatment metastatic disease . previous treatment chemotherapy metastatic disease allow ( three line , allow MTD Capecitabine one ) . previous treatment bisphosphonate allow . However , patient study received bisphosphonate receive Clodronate receive Pamidronate ; Pamidronate receive Zoledronate ; Zoledronate continue . '' The patient 's signature inform consent . Her2 neu positive tumor Inability visit clinic outpatient treatment evaluation Active/symptomatic brain metastasis . ECOG performance status : 24 . Presence Hand Foot syndrome , grade &gt; 2 . CBC grade &gt; 2 toxicity SMA show liver function &gt; 1.5 normal value SMA show renal function &gt; normal value Current continuous treatment steroid NSAIDs , anti coagulant `` non protocol '' reason . presence exclusively nonmeasurable disease ( I/E : exclusive bone disease nonrepresentative tumor marker ) . previous radiotherapy `` measurable disease '' . pleural peritoneal effusion may represent `` third space '' . history active peptic ulcer . symptomatic coronary heart disease .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>metronomic chemotherapy</keyword>
	<keyword>anti-angiogenic effect</keyword>
	<keyword>Breast cancer</keyword>
</DOC>